Mehdi Hamadani, MD

Professor of Internal Medicine

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital
Cancer Center - Moorland Reserve Health Center

Specialties

Hematology
Medical Oncology

Languages

English, Urdu, Hindi, Punjabi

Contact Information

Education

MD - Doctor of Medicine

Biography

Mehdi Hamadani, MD, is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology & Oncology, specializing in lymphoma, and bone marrow transplantation. Dr. Hamadani serves as the Director of the Adult Blood and Marrow Transplant Program (BMT) at Froedtert Hospital. He graduated from King Edward Medical College (with honors) in Pakistan in 2001, he then completed his internal medicine residency at Oklahoma University Health Sciences Center and a Fellowship in Hematology and Oncology at The Ohio State University. He received the James V. Warren Award for Accomplishments as The Most Outstanding Research Fellow, during his fellowship.

Research Interests

Dr. Hamadani has authored over 200 peer-reviewed publications, and has been invited as a speaker for several national and international meetings. He is the recipient of Conquer Cancer Foundation of ASCO Career Development Award and ASBMT New Investigator Award. Dr. Hamadani has also received several Best Attending Physician, Outstanding Teacher, Press Ganey Top Provider and Best Doctors in America Awards. His clinical research focuses on lymphoid malignancies and hematopoietic cell transplantation. Dr. Hamadani is board certified in Hematology and Medical Oncology.

Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?

(Shah NN, Ahn KW, Litovich C, He Y, Sauter C, Fenske TS, Hamadani M.) Blood. 2021 Mar 11;137(10):1416-1423 PMID: 33120429 PMCID: PMC7955408 SCOPUS ID: 2-s2.0-85102604135 10/30/2020
Breast Implant-associated Anaplastic Large Cell Lymphoma.

(Alotaibi S, Hamadani M, Al-Mansour M, Aljurf M.) Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):e272-e276 PMID: 33384263 01/02/2021
Bronchoalveolar lavage-based COVID-19 testing in patients with cancer.

(Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M.) Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020
Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

(Shah NN, Hamadani M.) J Clin Oncol. 2021 Feb 10;39(5):487-498 PMID: 33434076 SCOPUS ID: 2-s2.0-85102044262 01/13/2021
Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee.

(Sharma A, Badawy SM, Suelzer EM, Murthy HS, Prasad P, Eissa H, Carpenter PA, Hamadani M, Labopin M, Schoemans H, Tichelli A, Phelan R, Hamilton BK, Buchbinder D, Im A, Hunter R, Brazauskas R, Burns LJ.) Bone Marrow Transplant. 2021 Jan 29 PMID: 33514917 SCOPUS ID: 2-s2.0-85099909157 01/31/2021
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.

(Epperla N, Hamadani M.) Curr Hematol Malig Rep. 2021 Jan 25 PMID: 33492560 01/26/2021
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy.

(Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SO, Holtzman NG, Ii GLP, Devine SM, Mannis G, Grunwald MR, Appelbaum F, Rodriguez C, El Chaer F, Shah N, Hashmi SK, Kharfan-Dabaja MA, DeFilipp Z, Aljurf M, AlShaibani A, Inamoto Y, Jain T, Majhail N, Perales MA, Mohty M, Hamadani M, Carpenter PA, Nagler A.) Transplant Cell Ther. 2021 Jan;27(1):6-20 PMID: 32966881 09/24/2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.

(Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M.) Transplant Cell Ther. 2021 Jan;27(1):58-66 PMID: 32956819 PMCID: PMC7972998 SCOPUS ID: 2-s2.0-85093981145 09/22/2020
Allogeneic Transplant Conditioning Regimens for Patients With Non-Hodgkin Lymphoma-Reply.

(Hamadani M, Litovich C, Ahn KW.) JAMA Oncol. 2020 12 01;6(12):1984 PMID: 33151256 SCOPUS ID: 2-s2.0-85095867531 11/06/2020
Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

(Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid EG, O'Connor OA, Feingold J, Ardeshna KM, Townsend WM, Solh M, Heffner LT, Ungar D, Wang L, Boni JP, Havenith K, Qin YG, Kahl B.) Blood. 2020 Nov 19 PMID: 33211842 11/20/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.

(Abedin S, Hamadani M.) J Exp Pharmacol. 2020;12:549-557 PMID: 33273867 PMCID: PMC7705269 12/05/2020